Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Discrete pigmentation after chemotherapy.

Singal R, Tunnessen WW Jr, Wiley JM, Hood AF.

Pediatr Dermatol. 1991 Sep;8(3):231-5.

PMID:
1745634
2.

Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation.

Horn TD, Beveridge RA, Egorin MJ, Abeloff MD, Hood AF.

Arch Dermatol. 1989 Apr;125(4):524-7.

PMID:
2539058
3.

Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation.

Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ.

J Am Acad Dermatol. 2008 Apr;58(4):575-8. doi: 10.1016/j.jaad.2007.12.037. Epub 2008 Feb 4.

PMID:
18249465
4.
5.

High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer.

deMagalhaes-Silverman M, Rybka WB, Lembersky B, Bloom EJ, Lister J, Pincus SM, Voloshin M, Wilson J, Ball ED.

Am J Clin Oncol. 1996 Apr;19(2):169-73.

PMID:
8610643
6.

Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).

Meisenberg BR, Miller WE, McMillan R.

Bone Marrow Transplant. 1996 Dec;18(6):1087-93.

PMID:
8971377
7.

Combined intraarterial carboplatin, intraarterial etoposide phosphate, and IV Cytoxan chemotherapy for progressive optic-hypothalamic gliomas in young children.

Osztie E, Várallyay P, Doolittle ND, Lacy C, Jones G, Nickolson HS, Neuwelt EA.

AJNR Am J Neuroradiol. 2001 May;22(5):818-23.

8.

The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.

Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, Neuwelt EA.

Cancer J Sci Am. 1998 Mar-Apr;4(2):110-24.

PMID:
9532413
10.

Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.

Motzer RJ, Gulati SC, Tong WP, Menendez-Botet C, Lyn P, Mazumdar M, Vlamis V, Lin S, Bosl GJ.

Cancer Res. 1993 Aug 15;53(16):3730-5.

11.

Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.

Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG, Kumar PP, Warkentin PI, Gordon BG, Bierman PJ, et al.

Bone Marrow Transplant. 1991 Dec;8(6):489-95.

PMID:
1790429
12.

High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.

Antman K, Ayash L, Elias A, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper LE, Frei E 3rd.

J Natl Cancer Inst Monogr. 1994;(16):91-4.

PMID:
7528031
13.
14.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
15.

No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.

Massimino M, Gandola L, Spreafico F, Biassoni V, Luksch R, Collini P, Solero CN, Simonetti F, Pignoli E, Cefalo G, Poggi G, Modena P, Mariani L, Potepan P, Podda M, Casanova M, Pecori E, Acerno S, Ferrari A, Terenziani M, Meazza C, Polastri D, Ravagnani F, Fossati-Bellani F.

Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1358-63. doi: 10.1016/j.ijrobp.2008.06.1930. Epub 2008 Nov 18.

PMID:
19019566
16.

Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.

Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL.

Med Pediatr Oncol. 1996 Feb;26(2):95-100.

PMID:
8531860
17.

Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).

Rubie H, Michon J, Plantaz D, Peyroulet MC, Coze C, Frappaz D, Chastagner P, Baranzelli MC, Méchinaud F, Boutard P, Lutz P, Perel Y, Leverger G, de Lumley L, Millot F, Stéphan JL, Margueritte G, Hartmann O.

Br J Cancer. 1998 Jun;77(12):2310-7.

18.

High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study.

Saez RA, Slease RB, Strnad C, Selby GB, Confer DL, Epstein RB.

Bone Marrow Transplant. 1995 Oct;16(4):507-14.

PMID:
8528165
19.

Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.

Crilley P, Topolsky D, Styler MJ, Bernstein E, Resnick K, Mullaney R, Bulova S, Brodsky I, Marks DI.

Bone Marrow Transplant. 1995 Mar;15(3):361-5.

PMID:
7599559
20.

Intensive conditioning regimen for bone marrow transplantation in children with high-risk haematological malignancies.

Cole CH, Pritchard S, Rogers PC, Davis JE, Phillips G, Chan KW.

Med Pediatr Oncol. 1994;23(6):464-9.

PMID:
7935171

Supplemental Content

Support Center